Lexeo Therapeutics Inc. (LXEO): Market Capitalization-to-Revenue Ratio

Symbol and logo of brand lexeotx.com (LXEO)

Lexeo Therapeutics (LXEO) is implementing energy-efficient delivery and waste processing to comply with ESG standards. The company's P/S ratio demonstrates a balance between market demand and actual sales, with reflecting the metric's current value. The business is optimizing margins through overseas cardiology drug development centers while simultaneously reducing reliance on external viral vector suppliers to ensure the stability of clinical trials.

Price-to-Revenue Ratio: lexeotx.com (LXEO) for 07/04/2022 - 11/13/2026

Lexeo Therapeutics (LXEO) - metric breakdowns and financial figures

- current quotes and average value forecast:
Market Price lexeotx.com|LXEO - Price Target Chart
- stock exchange capitalization data:
Market Value Lexeo|LXEO - Enterprise Value
- book capitalization indicators:
Book Value per Share Lexeo Therapeutics|LXEO - Company Book Value|Market Capitalization to Net Assets lexeotx.com|LXEO - Company Total Assets
- debt obligations and liquidity statistics:
Debt to Capital Lexeo Therapeutics|LXEO - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital lexeotx.com|LXEO - Company Total Debt|Debt to Book Capital Lexeo|LXEO - Company Long-Term Debts|Short-Term Debt Volume Lexeo Therapeutics|Quick Liquidity Indicator lexeotx.com
- company profitability and valuation multiples indicators:
LXEO - Company Net Income|Company Profit Forecast Lexeo Therapeutics|LXEO - Price to Earnings Ratio|Future Price to Earnings lexeotx.com|LXEO - Price/Earnings to Growth Multiple|Enterprise Value to Operating Income Before Depreciation Lexeo|LXEO - Operating profit EBITDA|Net earnings per one share for the last twelve months Lexeo Therapeutics|LXEO - Earnings per share for the last twelve months|Earnings per share growth in annualized terms for the last twelve months lexeotx.com|LXEO - Earnings growth in current year|Projected earnings per share growth rate for next year Lexeo Therapeutics
- total revenue and sales volume data:
LXEO - Company Revenue|Company Revenue Forecast lexeotx.com|LXEO - P/S Multiple|Forward P/S Multiple Lexeo
Summary company analytics:Lexeo Therapeutics Inc.
Mass-produced product of Lexeo Therapeutics

Conservative capital prioritizes transparency in business valuation, which is why this indicator measures the company's value relative to its actual revenue, allowing for the identification of asset overvaluation amid market volatility. For Lexeo Therapeutics (LXEO), where synthesis automation is combined with the high cost of leading scientists' labor, analyzing the market capitalization-to-revenue ratio helps correlate current R&D expenditures with market expectations.

Competing companies

TEM - Price to Sales|Price-to-Revenue Ratio Qiagen QGEN|Market Capitalization-to-Revenue Ratio IONS|Repligen Corp. - P/S Multiple|RNA - P/S Multiple|CRISPR Therapeutics AG (CRSP) - Price-to-Revenue Ratio|Price-to-Sales Ratio WGS (genedx.com)|RARE (Ultragenyx) - P/S Multiple|Price to Sales Beam Therapeutics Inc BEAM|Market Cap to Revenue SRPT (Sarepta Therapeutics Inc)|P/S Multiple Twist Bioscience Corp (TWST)|10x Genomics, Inc. - Market Cap to Revenue|Market Cap to Sales Volume NTLA (intelliatx.com)|Stoke Therapeutics, Inc. - P/S Multiple|Price-to-Revenue Coefficient BioLife Solutions Inc BLFS|WVE: P/S Multiple|Market Cap to Revenue Maze Therapeutics Corp|Price-to-Revenue Ratio Sionna Therapeutics Inc|primemedicine.com (PRME) - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Taysha Gene Therapies, Inc. (TSHA)|Price-to-Revenue Ratio QURE (uniQure NV)|MeiraGTx PLC - Market Cap to Revenue|RGNX: Market Cap to Revenue Ratio|Solid Biosciences Inc. - P/S Multiple|Price to Sales ocugen.com|PacBio (PACB) - Price-to-Revenue Ratio|Price to Sales Benitec Biopharma Inc (BNTC)|DSGN (Design Pharma) - P/S Multiple|Market Cap to Revenue Ratio RCKT (Rocket Corp)|Price-to-Revenue Ratio 4D Molecular Therapeutics (FDMT)|korrobio.com - Market Cap to Revenue Ratio|P/S Multiple EDIT (Editas Medicine)|P/S Multiple Silence Therapeutics PLC SLN|PRQR - Price-to-Revenue Ratio|CDXS: Price-to-Revenue Ratio|SGMO: P/S Multiple|Price to Sales Nautilus Bio (NAUT)|Market Cap to Revenue MGX|Market Cap to Revenue Ratio DTIL (precisionbiosciences.com)|P/S Multiple GBIO|BOLD - Price to Sales|Price-to-Revenue Ratio Exicure XCUR|Imunon Inc (IMNN) - Price to Sales|PHIO: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio MBIO (Mustang Bio, Inc.)|RNAZ (transcodetherapeutics.com) - Market Cap to Revenue|BNGO: Market Cap to Sales Volume|APDN (Applied DNA Sciences) - P/S Multiple|BLUE: Market Capitalization-to-Revenue Ratio|P/S Multiple IPA|OMGA - Price to Sales|Price-to-Revenue Ratio Singular Genomics Systems Inc OMIC|Market Capitalization-to-Revenue Ratio RGLS|Syros Pharmaceuticals - P/S Multiple|TBIO - P/S Multiple|TRACON Pharmaceuticals, Inc. (TCON) - Price-to-Revenue Ratio|Price-to-Sales Ratio UBX (Unity Biotechnology Inc.)